ProfileGDS5678 / 1428547_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 84% 82% 82% 78% 86% 73% 83% 84% 82% 87% 87% 86% 84% 88% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 16.1284584
GSM967853U87-EV human glioblastoma xenograft - Control 25.999582
GSM967854U87-EV human glioblastoma xenograft - Control 35.9345982
GSM967855U87-EV human glioblastoma xenograft - Control 45.4687578
GSM967856U87-EV human glioblastoma xenograft - Control 56.5751786
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 14.5943373
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 25.9556883
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 36.2174584
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 45.9975982
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 16.7037987
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 26.6505587
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 36.5722986
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 46.1677884
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 56.8834888